Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
DaVita ( (DVA) ) has issued an update.
On June 5, 2025, DaVita Inc. held its virtual 2025 Annual Meeting of Stockholders, where approximately 90% of its outstanding shares were represented. During the meeting, stockholders elected nine directors to the board, ratified KPMG LLP as the independent accounting firm for 2025, and approved the executive officer compensation on an advisory basis.
The most recent analyst rating on (DVA) stock is a Sell with a $145.00 price target. To see the full list of analyst forecasts on DaVita stock, see the DVA Stock Forecast page.
Spark’s Take on DVA Stock
According to Spark, TipRanks’ AI Analyst, DVA is a Neutral.
DaVita’s overall stock score is influenced primarily by its strong financial performance, particularly robust cash flow, and strategic corporate events aimed at financial flexibility. However, high financial leverage poses a risk, and technical indicators suggest potential bearish trends. The balanced earnings call with both achievements and challenges further supports a moderate score.
To see Spark’s full report on DVA stock, click here.
More about DaVita
DaVita Inc. operates in the healthcare industry, primarily providing kidney care services, including dialysis treatments. The company focuses on improving the quality of life for patients with chronic kidney disease and end-stage renal disease.
Average Trading Volume: 851,984
Technical Sentiment Signal: Buy
Current Market Cap: $10.41B
Learn more about DVA stock on TipRanks’ Stock Analysis page.